drugset
Drugs / insulin degludec/insulin aspart
last change Oct 2016 re-read 2 minutes ago

insulin degludec/insulin aspart

also known as IDegAsp · NN5401 · SIAC

Protein / enzyme biologic

Developed for
type 2 diabetes mellitus
Investigated by
Novo Nordisk A/S

Trials 1 · a red edge is where a trial was stopped

today NCT00842361 · Ph 2
2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00842361 Jan → Jun 2009 type 2 diabetes mellitus Novo Nordisk A/S Completed No outcome recorded

Press releases naming this drug 16 releases

DateIssuerRelease
2013-01-21 Novo Nordisk A/S Tresiba® (insulin degludec) og Ryzodeg® (insulin degludec/insulin aspart) får markedsføringstilladelse i Europa novonordisk.com ↗
2012-12-25 Novo Nordisk A/S Ryzodeg® (insulin degludec/insulin aspart) approved in Japan novonordisk.com ↗
2012-12-25 Novo Nordisk A/S Ryzodeg® (insulin degludec/insulin aspart) godkendt i Japan novonordisk.com ↗
2012-12-03 Novo Nordisk A/S Ryzodeg® (insulin degludec/insulin aspart) passed review by First Committee on Drugs of Pharmaceutical Affairs in Japan novonordisk.com ↗
2012-12-03 Novo Nordisk A/S Ryzodeg® (insulin degludec/insulin aspart) passerer evaluering i japansk medicinkomite novonordisk.com ↗
2012-11-08 Novo Nordisk A/S Insulin degludec and insulin degludec/insulin aspart receive positive vote for approval from FDA Advisory Committee novonordisk.com ↗
2012-11-06 Novo Nordisk A/S FDA offentliggør briefingmateriale forud for mødet i den rådgivende komite om insulin degludec og insulin degludec/insulin aspart novonordisk.com ↗
2012-11-06 Novo Nordisk A/S FDA posts briefing materials prior to Advisory Committee meeting for insulin degludec and insulin degludec/insulin aspart novonordisk.com ↗
2012-10-25 Novo Nordisk A/S FDA offentliggør fokus for mødet i den rådgivende komite om insulin degludec og insulin degludec/insulin aspart novonordisk.com ↗
2012-10-25 Novo Nordisk A/S FDA discloses focus of Advisory Committee meeting on insulin degludec and insulin degludec/insulin aspart novonordisk.com ↗
2012-10-19 Novo Nordisk A/S Novo Nordisk modtager positive udtalelser om Tresiba® (insulin degludec) og Ryzodeg® (insulin degludec/insulin aspart) fra de europæiske registreringsmyndigheder novonordisk.com ↗
2012-10-19 Novo Nordisk A/S Tresiba® (insulin degludec) and Ryzodeg® (insulin degludec/insulin aspart) receive positive opinions from the European regulatory authorities novonordisk.com ↗

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as insulin degludec/insulin aspart ClinicalTrials.gov intervention name — accepted as the source's own label NCT00842361 ↗
Known as IDegAsp “Insulin degludec/insulin aspart (IDegAsp) is a soluble combination of insulin degludec (70%) and insulin aspart (30%).” PMID 27560769 ↗ Oct 2016
Known as NN5401 “This trial is conducted in Japan. The aim of this clinical trial is to investigate the safety (with emphasis on hypoglycaemia) after switching from long-acting insulin...” NCT00842361 ↗
Known as SIAC “This trial is conducted in Japan. The aim of this clinical trial is to investigate the safety (with emphasis on hypoglycaemia) after switching from long-acting insulin...” NCT00842361 ↗
Modality Protein / enzyme biologic “The insulin NN5401 (insulin degludec/insulin aspart) injected subcutaneously immediately before breakfast and dinner.” NCT00842361 ↗
Route Subcutaneous “injected subcutaneously immediately before breakfast and dinner” NCT00842361 ↗